Literature DB >> 12040012

Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation.

Roberto Lin1, Yoshihiko Nagai, Robert Sladek, Yolande Bastien, Joanne Ho, Kevin Petrecca, Georgia Sotiropoulou, Eleftherios P Diamandis, Thomas J Hudson, John H White.   

Abstract

The active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is key mediator of calcium homeostasis and is a component of the complex homeostatic system of the skin. 1,25-(OH)2D3 regulates cellular differentiation and proliferation and has broad potential as an anticancer agent. Oligonucleotide microarrays were used to assess profiles of target gene regulation at several points over a 48 h period by the low calcemic 1,25-(OH)2D3 analog EB1089 in human SCC25 head and neck squamous carcinoma cells. One hundred fifty-two targets were identified, composed of 89 up- and 63 down-regulated genes distributed in multiple profiles of regulation. Results are consistent with EB1089 driving SCC25 cells toward a less malignant phenotype, similar to that of basal keratinocytes. Targets identified control inter- and intra-cellular signaling, G protein-coupled receptor function, intracellular redox balance, cell adhesion, and extracellular matrix composition, cell cycle progression, steroid metabolism, and more than 20 genes modulating immune system function. The data indicate that EB1089 performs three key functions of a cancer chemoprevention agent; it is antiproliferative, it induces cellular differentiation, and has potential genoprotective effects. While no evidence was found for gene-specific differences in efficacy of 1,25-(OH)2D3 and EB1089, gene regulation by 1,25-(OH)2D3 was generally more transient. Treatment of cells with 1,25-(OH)2D3 and the cytochrome P450 inhibitor ketoconazole produced profiles of regulation essentially identical to those observed with EB1089 alone, indicating that the more sustained regulation by EB1089 was due to its resistance to inactivation by induced 24-hydroxylase activity. This suggests that differences in action of the two compounds arise more from their relative sensitivities to metabolism than from differing effects on VDR function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040012     DOI: 10.1210/mend.16.6.0874

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Eldecalcitol (ED-71), an analog of 1α,25(OH)2D3, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) and FGF-2.

Authors:  T Shintani; F Takatsu; S N Z Rosli; E Usui; A Hamada; K Sumi; Y Hayashido; S Toratani; Tetsuji Okamoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-07-14       Impact factor: 2.416

3.  Convergence of vitamin D and retinoic acid signalling at a common hormone response element.

Authors:  Luz Tavera-Mendoza; Tian-Tian Wang; Benjamin Lallemant; Rui Zhang; Yoshihiko Nagai; Véronique Bourdeau; Mario Ramirez-Calderon; Julie Desbarats; Sylvie Mader; John H White
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

Review 4.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

5.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

6.  Epigenetic inactivation of galanin receptor 1 in head and neck cancer.

Authors:  Kiyoshi Misawa; Yo Ueda; Takeharu Kanazawa; Yuki Misawa; Ilwhan Jang; John Chadwick Brenner; Tetsuya Ogawa; Satoru Takebayashi; Reidar A Grenman; James G Herman; Hiroyuki Mineta; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 7.  Vitamin D signaling, infectious diseases, and regulation of innate immunity.

Authors:  John H White
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 8.  Vitamin D receptor and RXR in the post-genomic era.

Authors:  Mark D Long; Lara E Sucheston-Campbell; Moray J Campbell
Journal:  J Cell Physiol       Date:  2015-04       Impact factor: 6.384

9.  1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1.

Authors:  Pavlo L Kovalenko; Zhentao Zhang; Min Cui; Steve K Clinton; James C Fleet
Journal:  BMC Genomics       Date:  2010-01-13       Impact factor: 3.969

10.  Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140.

Authors:  Kelly C Heim; Joshua J Gamsby; Mary P Hever; Sarah J Freemantle; Jennifer J Loros; Jay C Dunlap; Michael J Spinella
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.